State of The Art
Hip Knee J. Vol. 4, No. 1, 2023, pp. 4-11
p-ISSN: 2723-7818
e-ISSN: 2723-7826
http://dx.doi.org/10.46355/hipknee.v4i1.150

ECONOMIC BURDEN OF PERIPROSTHETIC JOINT INFECTION

Dicky Mulyadi[1], Magetsari RMSN[2]

[1,2] Department of Orthopedics and Traumatology, Adult Reconstruction Division Faculty of Medicine, Universitas Padjadjaran / Dr. Hasan Sadikin General Hospital Bandung, Indonesia.

ABSTRACT

Total knee arthroplasties (TKAs) and total hip arthroplasties (THAs) have been proven to help improving the quality of life of numerous patients and have been regarded as successful standard operations in orthopaedic surgeries. However, there is still a lingering devastating complication in the form of peri-prosthetic joint infection (PJI). This condition can be difficult to diagnose and may present at any time after arthroplasty requiring surgical intervention, often multiple times. Surgical revisions due to infection requires multiple visits and longer length of stay resulting in greater hospital costs.

As the number of arthroplasty procedures increases so does the number of PJIs and therefore revisions. In 2010 there were estimated 8 136 PJI cases associated with hips and 17 781 cases associated with the knee and it is projected to grow in 2020 to be 16 584 cases for hip and 48 971 cases for knee. This also translated in the increase of estimated cost from around $785 million in 2010 to $1.62 billion in 2020.

Keywords: Periprosthetic Joint Infection, Total Knee Arthroplasty, Total Hip Arthroplasty, Economic Burden.

Article History:

Submission : February 23th, 2023
Revision : February 23th, 2023
Accepted : February 27th, 2023

Corresponding Author:

Dicky Mulyadi
Department of Orthopedics and Traumatology, Adult Reconstruction Division Faculty of Medicine, Universitas Padjadjaran / Dr. Hasan Sadikin General Hospital Bandung, Indonesia.
dickymul@yahoo.com

INTRODUCTION

Total knee arthroplasties (TKAs) have improved the quality of life for many sufferers and are regarded as effective orthopaedic procedures. Despite advancements in surgical methods and atmospheres, peri-prosthetic infections continue to be worried as serious issues following TKA. Profound infection accounts for approximately twenty per-cent of revision TKA procedures. The documented occurrence ranges from a half to one per-cent. Several risk factors for profound infection after TKA diagnosed, involving a man, rheumatoid arthritis (RA), an American Society of Anaesthesiologists (ASA) risk score more than two, and pathological fattiness. Early and delayed TKA infections are the most prevalent form of infection. Staphylococcus aureus and coagulase-negative staphylococci are pathogens most secluded, accounting for up to fifty-eight per-cent of periprosthetic TKA infections. In addition to the painful impact to sufferer, there is a colossal economic impact on the treating institution (1,2).

Periprosthetic joint infection (PJI) has become the most difficult problem of total joint arthroplasty in this twenty first millennium and, from the sufferers', physicians', infirmaries', and health system's points of view, the most serious. PJI's complications are diverse. Diagnosing periprosthetic joint infection could be challenging. It could manifest suddenly following index arthroplasty and need an operation treatment, frequently multiplication procedures, to manage. Compared to other forms of revision surgery, it takes a heavier amenability on infirmary and physician resources. The actual economic impact of PJI on U.S. medical service is presently not found, as tiny relevant researches have been published (3).

Contrast to fixation for aseptic stretch, revisions for infection result in infirmary calls, protractedly length of settle, and bigger infirmary expenditure. Infection is identified around fifteen per-cent of impairment total hip arthroplasty (THA) in the United States, making it to position number three as the most common fixation cause, according to recent national inpatient data. Epidemiologic studies suggest that the occurrence of PJI might growing in the United States, despite the disease's rarity. The pool of at-risk patients is increasing due to the compounding impacts of elevated procedure application and increased THA patient longevity. Therefore, it is essential to comprehend the tentative risk factors for PJI (4).

Kurtz et al. inspect the prevalence of PJI in the United States by using Nationwide Inpatient Sample (NIS), an inpatient record managed by a Center for Healthcare Assurance and Studies that is nationally generalizable. The prior explanation was restricted to US dataset among 1993 to 2004, omitted the initial stage of a two-stage refinement for inflammation, and only involved infirmary fees, as opposed to the suspected expenses involved with infection changes (5).

The update amenability, set as the ratio of refinement arthroplasties to all number of arthroplasties, has kept comparatively

stable more than last 13 years, despite a growing in the amount of refinement total pelvic and patella arthroplasties conducted in the United States. Prior explanation of national dataset on the processes demonstrated that amongst 1990 and 2002, the update amenability for total hip arthroplasty around 17.5%, while the refinement amenity for total patella arthroplasty was nearly eight point two per-cent(1). Economically, refinement total pelvic arthroplasty is expected to have accounted for nineteen percent of Medicare pelvic substitution costs among 1997 and 2003, while revision total knee arthroplasty accounted for just eight per-cent of Medicare's annual patella substitution costs (6).

The Incidence of Prosthetic Joint Infection
The rate of PJI changes based on affected joint. Occurrence observed after total knee arthroplasty, total hip arthroplasty, and total shoulder arthroplasty range from 0.25 to 2 percent, 0.5% to 1 percent, and less than 1 percent, respectively. PJI is performed in twenty-three to twenty-five per-cent of refinement TKA methods and twelve to fifteen per-cent of refinement THA methods. The health issues for PJI are shown in Table 1. Even though, as the annual amount of arthroplasty processes conducted elevated, the patients being treated is expected to rise over time (7).

The incidence of PJI varies among published studies. Consequently, existing data must be interpreted with care. Wang et al. found that the occurrence of PJI decreased from one point nine to zero point seventy-six per-cent among 2006 to 2014. Runner et al. also stated that the occurrence of PJI decreased from one point four to zero point six per-cent among 2008 to 2016. Contrary to statements from the United States National Inpatient Sample, the occurrence of PJI in sufferers undergoing THA growing from one point ninety-nine to two point eighteen per-cent between 2001 until 2009, and from 2.05% to 2.18 % for those undergoing TKA. Between 1999 and 2009, the Nordic Arthroplasty Registry stated that the rate of refinement methods for infected THA increased to zero-point seventy-one percent. Infection remains one of the top five reasons for refinement operation, according to all major joint registries. It is evident from the prior reference that the annual number of total pelvic and patella arthroplasties is rising (1,7). The frequencies of these methods transforms the comparatively slight occurrence of PJI to a huge amenity for clinicians and institutions. The evolving physiologic status of client showing for total joint arthroplasty is less controversial. Between 2010 and 2018, the number of clients classified as American Society of Anaesthesiologists (ASA) Class 1 (fit and robust) reduced from sixteen to twelve percent. During the similar time, the proportion of clients classified as ASA Class 3 (disabling systemic illness) elevated from fifteen to twenty percent (7). In the field of reconstructive orthopaedics, PJI is becoming a growing concern. The related fatality rate at 90 days around 4%, contrasted to 0.3% after primary total pelvic and patella arthroplasty (2,4,6).



Figure 1 The mortality associated with PJI compared to common cancers. PJI, prosthetic joint infection (7).

The fatality rates related with PJI are alarmingly high. Patients diagnosed with hip PJI have a reported mortality rate of 24 to 26%. In thirty to ninety days (three point seven vs. zero point eight per-cent) and ninety days to one-year (ten vs. two per-cent). Parvizi et al. discovered a statistically significant difference in mortality rates between correction for PJI and aseptic shedding. PJI has a mortality rate comparable to that of breast carcinoma and bigger than those of colorectal and pulmonary carcinoma (Figure 1.) (2,4,6). Multiple risk factors for post-THA PJI has identified by clinical studies. Compared to privately insured patients, patients with predominantly poor county health coverage and Medicaid have a higher risk of infection.

Fattiness have been entangled as an independent risk factor, even women may be more susceptible to its effects. PJI is also prevalent in people with diabetic and several health comorbidities. It has been reported that procedure-related factors, as well as prolonged surgery duration or the absence of antibiotic-impregnated cement, increase the risk of PJI (8–10). Despite the fact that these researches supplied a comprehension of the risk factors for PJI from the perspective of a singular agency or worldwide entrant, they are not explained from a national point of view in the United States. In addition, the majority of the researches assessed the risk of premature infections. Unknown is whether the same risk factors apply to late infections. Taking a national medical services record, the incidence and prevalence of PJI were also quantified, but the timeline of PJI identification for the entire sufferer was unknown.

Current health or community database have produced contradictory results. One stated that the cumulative rate of profound infection peak within the initial month or annual after surgery, while others have discovered that the majority of PJIs are identified after one-year post-surgery. Recognizing the timing of PJI will aid physician in managing PJI clients and optimizing management for a tough problem. This investigation aimed to determine the occurrence of initial-begin (I< two years) and late-begin (> two years) PJI in the Medicare people with up to ten years of follow-up after primary THA. We investigated the predisposing risk factors for PJI (4).

Table 1. Factors predisposing to prosthetic joint infection

Factors which are potentially associated with prosthetic joint infection
Male gender
Age <60
ASA Score >3
Chronic Obstructive Pulmonary Disease (COPD)
Diabetes mellitus
Liver failure
Connective tissue disease
Peripheral vascular disease

Previous septic arthritis
Previous surgery for trauma to the same joint
Inflammatory arthropathy
General anaesthetic use of tibial bone graft
Use of tibial bone graft
Use of posterior stabilised knee prosthesis
Use of constrained condylar knee prosthesis

Progression Of PJI the Poisson regression model predicted the speed of operation as a function of the sufferer's age, gender, ethnicity, and geographical spot, in addition to adapting for the sort of operation (THA/TKA; primary/refinement) and whether illness was detected (2,9,11). This rate may fluctuate straight as the time goes by. Interconnection between demographic and operation factors and calendar year were also incorporated into the Poisson model, granting for distinct tendency between demographic and operation category in the data.

Consequently, the upcoming amount of infected and uninfected THA or TKA is predicted using "scoring" the model-estimated rates against the upcoming number of people supplied by the Census Bureau. Estimating the amount of infected incident beyond 2009 involves adding the predicted amount of incident in every demographic and operation category. Believing autonomous between subgroups, a crude CI of the general is derived by adding the predicted variance of every element estimate supplied by the model as the variance of the total (2,4).

The dotted marks symbolize the projected values for each category of surgery, which 95% confidence intervals for the historical prediction (2001-2009) and statistic projections (2010-2020) (2), in 2001, the corresponding incidence rates were 2.05% (CI: 1.86%-2.23%) and in 2009, they were 2.18% (CI: 1.99%-2.33%). Knee arthroplasty cases showed a gradually with meaningful elevation in infection risk over time compared to hip arthroplasty incident (odds ratio, 1.016; P =.003).(8–10,12).



Figure 2. Numbers of infected THA, TKA, and total (THA + TKA) methods performed in the US over time and in the future (2001-2020).

Costs Burden Of PJI in spite of the rise in the incidence of PJI, one study found that the average duration of settle for pelvic sufferers lower from 11.5 days (CI: 10.3-12.7) in 2001 to 9.5 days (CI: 8.8-10) in 2009. Similarly, the length of stay for knee patients with PJI decreased from 9.3 days (CI, 8.2-10.4) in 2001 to 7.2 days (CI, 6.8-7.5) in 20098–10. Despite an evident growing in the overall quantity of hospital fees, the predicted infirmary expenditures to manage PJI incident stay comparatively stabile during the study time. In US, the average cost for pelvic patients was $31 300 ($28 300-$34 300) in 2001 and $30 300 ($27 600-$33 000) in 2009. The mean of all fees for revision of an infected pelvic were $72,700 in 2001 and $93,600 in 2009. Patients with PJI of the knee had, on average, lower treatment expenses than

those with PJI of the hip. In 2009, the mean hospitalization expenditure for patella sufferers with PJI was $24 200 ($22 800-$25 600), compared to $25 300 ($22 500-$28 100) in 2001. Comparatively, the average fees were $58 700 in 2001 and $74 900 in 2009 (8–10,12).

Based on a prior study in the United States, the mean price gap among knee and hip PJI cases was $5965, and following managing for other patient factors, this price gap did not change significantly among 2001 and 2009. The geographic census area in which the sufferer resided also had a meaningful impact on the expenditures of managing PJI arthroplasty incidents (8–10). Patients residing in the South or the Midwest in the United States had a discounted rate ($4000-$5000) than those residing in the West or the Northeast (8–10). According to an earlier finding, minority people of any ethnicity incurred substantially greater prices than white patients. Asian patients were linked to roughly $4700 more expenses than white patients on usual, and African American clients were linked with around $1700 more than white race on typicall (2).

Curiously, neither age nor gender alone was a meaningful for the hospitalization expenditures of PJI, but the interaction between the two was (8–10). At a particular age, female patients had greater PJI management expenses than others. However, this diversity lessened as age increased. For an illustration, a female client between the ages of 45-54 invited an extra fee of approximately $3800. This difference was reduced to $1800 for patients between the ages of 75 and 79 (8–10).

According to data from the United States, at the beginning of this decade (2010), an estimated 8136 (7832-8441) hip-related PJI cases and 17 781 knee-related PJI cases (17 098-18 464) were anticipated. Last year of 2020, the amount of PJI incident associated with hips is predicted to be 16 584 (CI, 15 081-18 087) and the number linked to knees is projected to be 48 971 (CI, 44 647- 53 297). In 2020, 60 000 to 70 000 incidents of PJI linked to pelvic or patella arthroplasty would necessitate management nationwide(8–10). In 2009, the predicted for overall infirmary expenditures for healing PJI was $560,000,000 compared to $320 million in 2001. Forthcoming PJI incident are anticipated to expense U.S. infirmaries approximately $785,000,000 ($769-802 million) in 2010 and $1.62 billion ($1.53-1.72 billion) in 2020, due to infirmary expenditures estimates derived from current dataset. By 2014, this cost would reach $1 billion.



Figure. 3. Previous and predicted future overall inpatient costs of infected THA, TKA, and THA and as well as TKA procedures performed in the United States (2001-2020).

Taking the Consumer Price Index, the entire expenditures (in millions of USD) is conformed to 2011 prices. The dashed lines represent the projected values for each category of surgery, and the dotted lines reflect the 95% confidence intervals for the previous prediction (2001-2009) and statistic estimations (2010-2020) (8–10).

Periprosthetic joint infection remains a significant obstacle for the health communities. Recent treatment choice for PJI are not complete. Clients with PJI undergo multiple surgical procedures with varying degrees of efficacy. Current "gold standard" treatment for chronic PJI of the pelvic and patella is two-stage replace arthroplasty with an effective number around sixty-five to ninety percent (11,13–15). Consequently, there is a subset of clients who, despite having undergone several operations, keep going to suffer from PJI and require salvage processes such as fusion, resection arthroplasty, or amputation. A growing society in the US and the sustained adaptive and acquiescence of total joint arthroplasty as a choice of management for degenerative joint situations are anticipated to prepare increased overall number of arthroplasties carried-out and, consequently, the estimated all amount of PJI incident that will needs future medical attention over the next ten years (8,11,15,16).

The Registry data set and various studies concerning the impact of PJI on cpsts have significant limitations. As with any research using national administrative claims databases, insufficient clinical data collection linked to PJI limits some studies. While the exactness of PJI coding in regulatory invoices data was currently confirmed, the invoices data are confined to ICD-9-CM methods and diagnostic codes and thus do not cover health examination pertinent to PJI, as well as the causative organism.

The anticipated infirmary expenditures in this research are not involved the expense of orthopedic surgeons' operation procedures or other doctors' services (eg, infection specialists and anesthesiologists). In addition, expenditures for following treatment, physical management and training, home visits, and pharmacology therapeutic were not included. In terms of cost estimations, the economic amenity of infection presented in the current research certainly underestimated. The utilization of a huge and national reflective data collection of infirmary discharge is a fundamental strength of these investigations.

CONCLUSION

Secretomes produced by umbilical cord mesenchymal stem cells can stimulate the repair of cartilage damage, anti-inflammatory, immunomodulator, angiogenesis, and antiapoptotic abilities from their cytokines and extra vesicles containing miRNA. UC-MSC secretomes are more stable and provide simpler manufacturing than UC-MSCs themselves. They are also rich in cytokines and miRNA that can be a potential therapy for OA in the future.

REFERENCE

1. Haenle M, Skripitz C, Mittelmeier W, Skripitz R. Clinical Study : Economic

Impact of Infected Total Knee Arthroplasty. Sci World J. 2012;2012.
2. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. Vol. 89, Journal of Bone and Joint Surgery. 2007. p. 780–5.
3. Gupta N, Gupta TT, Patel K, Stoodley P. The Influence of Patterned Surface Features on the Accumulation of Bovine Synovial Fluid-Induced Aggregates of Staphylococcus aureus. Appl Environ Microbiol. 2022;88(22).
4. Ong KL, Kurtz SM, Lau E, Bozic KJ, Berry DJ, Parvizi J. Prosthetic Joint Infection Risk After Total Hip Arthroplasty in the Medicare Population. 2009;24(6):105–9.
5. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. Economic burden of periprosthetic joint infection in the united states. J Arthroplasty. 2012;27(8 SUPPL.):61–6.
6. Kurtz S, Ong K, Lau E, Mowat F, Halpern M. Projections of Primary and Revision Hip and Knee Arthroplasty in the United States from 2005 to 2030. J BONE Jt Surg. 2007;89:780–5.
7. Francescini NAS, Kendoff I. The burden of prosthetic joint infection (PJI). Ann Jt. 2021;2030(1):25–8.
8. Kurtz SM, Ong KL, Schmier J, Mowat F, Saleh K, Dybvik E, et al. Future clinical and economic impact of revision total hip and knee arthroplasty. Vol. 89, Journal of Bone and Joint Surgery. 2007. p. 144–51.
9. Kurtz SM, Lau E, Ong K, Zhao K, Kelly M, Bozic KJ. Future young patient demand for primary and revision joint replacement: National projections from 2010 to 2030. Vol. 467, Clinical Orthopaedics and Related Research. 2009. p. 2606–12.
10. Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. Infection Burden for Hip and Knee Arthroplasty in the United States. J Arthroplasty. 2008;23(7):984–91.
11. Parvizi J, Pawasarat IM, Azzam KA, Joshi A, Hansen EN, Bozic KJ. Periprosthetic joint infection: The economic impact of methicillin-resistant infections. Vol. 25, Journal of Arthroplasty. 2010. p. 103–7.
12. Bozic KJ, Chiu VW, Takemoto SK, Greenbaum JN, Smith TM, Jerabek SA, et al. The Validity of Using Administrative Claims Data in Total Joint Arthroplasty Outcomes Research. Vol. 25, Journal of Arthroplasty. 2010. p. 58–61.
13. Bozic KJ, Ries MD. The impact of infection after total hip arthroplasty on hospital and surgeon resource utilization. J Bone Jt Surg. 2005;87(8):1746–51.
14. George DA, Haddad FS. Surgical management of periprosthetic joint infections: two-stage exchange. J Knee Surg. 2014;27(4):279–82. 15. Parvizi J, Zmistowski B, Adeli B. Periprosthetic joint infection: treatment options. Vol. 33, Orthopedics. 2010. p. 659.
15. Fehring TK, Odum SM, Troyer JL, Iorio R, Kurtz SM, Lau EC. Joint Replacement Access in 2016. A Supply Side Crisis. Vol. 25, Journal of Arthroplasty. 2010. p. 1175–81.